MGP
MRNA icon

Metis Global Partners’s Moderna MRNA Stock Holding History

Metis Global Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$452K Sell
6,452
-90
-1% -$4.66K 0.01% 579
2026
Q1 		$332K Sell
6,542
-999
-13% -$46.6K 0.01% 628
2025
Q4 		$222K Sell
7,541
-235
-3% -$6.38K 0.01% 712
2025
Q3 		$201K Sell
7,776
-276
-3% -$7.7K ﹤0.01% 731
2025
Q2 		$222K Sell
8,052
-6,368
-44% -$168K 0.01% 700
2025
Q1 		$409K Sell
14,420
-5,656
-28% -$201K 0.01% 623
2024
Q4 		$835K Buy
20,076
+5,242
+35% +$251K 0.03% 480
2024
Q3 		$991K Buy
14,834
+1,814
+14% +$167K 0.03% 441
2024
Q2 		$1.55M Buy
13,020
+779
+6% +$98.6K 0.05% 316
2024
Q1 		$1.3M Sell
12,241
-141
-1% -$14.2K 0.05% 362
2023
Q4 		$1.23M Sell
12,382
-3,082
-20% -$259K 0.05% 357
2023
Q3 		$1.6M Buy
15,464
+2,493
+19% +$278K 0.08% 274
2023
Q2 		$1.58M Buy
12,971
+3
+0% +$400 0.08% 250
2023
Q1 		$1.99M Buy
12,968
+3,431
+36% +$566K 0.13% 162
2022
Q4 		$1.71M Buy
9,537
+3,590
+60% +$587K 0.15% 146
2022
Q3 		$704K Buy
5,947
+386
+7% +$58.6K 0.11% 202
2022
Q2 		$794K Buy
5,561
+31
+0.6% +$4.43K 0.13% 186
2022
Q1 		$953K Buy
5,530
+2,450
+80% +$412K 0.11% 169
2021
Q4 		$782K Buy
+3,080
New +$901K 0.22% 104

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Metis Global Partners's MRNA Position: Q2 2026 in Review

Metis Global Partners reduced its Moderna (MRNA) stake by 1.4% in Q2 2026, selling an estimated $4.66K and leaving 6,452 shares worth $452K. The position accounts for 0.01% of the portfolio, ranked #579.

Metis Global Partners first reported a position in MRNA in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.99M in Q1 2023. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Metis Global Partners held 6,452 shares of Moderna worth $452K as of Q2 2026.
  • Metis Global Partners sold 90 Moderna shares in Q2 2026, an estimated $4.66K.
  • Moderna made up 0.01% of Metis Global Partners's portfolio in Q2 2026, its #579 holding.
  • Metis Global Partners first reported a position in Moderna in Q4 2021 and has held it in 19 quarters since.
  • Metis Global Partners's Moderna position peaked at $1.99M in Q1 2023.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Metis Global Partners's 13F filing for Q2 2026, filed 10 Aug 2026.